Universal American Corp (NYSE:UAM) shares moved down -3.46% in last trading session and ended the day at $6.14. UAM has a return on assets of -1.30%. Universal American Corp (NYSE:UAM) quarterly performance is -12.03%.
Universal American Corp (NYSE:UAM) said that, it is projected to report earnings of $0.03 for its recent quarter. The company plans to release its quarterly report on or around 2016-02-17.
Tasman Metals Ltd. (NYSEMKT:TAS) ended the last trading day at $0.16. Company weekly volatility is calculated as 11.20%. Tasman Metals Ltd. (NYSEMKT:TAS) showed a weekly performance of -1.35%.
Tasman Metals Ltd. (NYSEMKT:TAS) announces its intention to file a Form 25 (Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934) with the U.S. Securities and Exchange Commission (the ‘SEC’) to voluntarily withdraw its common shares from listing on the NYSE MKT LLC (‘NYSE MKT’).
On 27 January, Graham Corporation (NYSE:GHM) shares moved up 0.67% and was closed at $16.65. GHM EPS growth in last 5 year was 17.80%. Graham Corporation (NYSE:GHM) year to date (YTD) performance is -1.01%.
Graham Corporation (NYSE:GHM) announced that it will release its financial results for the third quarter of fiscal year 2016, which ended December 31, 2015, before the opening of financial markets on Friday, January 29, 2016.
Radius Health, Inc. (NASDAQ:RDUS) shares moved down -11.21% in last trading session and ended the day at $31.14. RDUS has a return on assets of -31.70%. Radius Health, Inc. (NASDAQ:RDUS) quarterly performance is -51.76%.
Radius Health, Inc. (NASDAQ:RDUS) announced that it has entered into a worldwide clinical collaboration with Novartis Pharmaceuticals (NYSE:NVS) to evaluate the safety and efficacy of combining investigational agent RAD1901, a novel oral selective estrogen receptor degrader (SERD), with investigational agent LEE011 (ribociclib)*, a cyclin-dependent kinase (CDK) 4/6 inhibitor. Preclinical studies of RAD1901 have shown consistent and robust single agent anti-tumor activity in multiple wild type and ESR1-mutant breast cancer models and tumor regression when combined with targeted agents such as CDK 4/6 inhibitors in pre-clinical models.
SunCoke Energy Inc. (NYSE:SXC) caters to the Basic Materials space. It has a net profit margin of -7.60% and weekly performance is 1.77%. On the last day of trading company shares ended up at $2.30. SunCoke Energy Inc. (NYSE:SXC) distance from 50-day simple moving average (SMA50) is -29.88%.
SunCoke Energy Inc. (NYSE:SXC) declared a fourth quarter 2015 cash distribution of $0.5940 per limited partnership unit, or $2.38 annualized. The fourth quarter 2015 distribution will be payable on March 1, 2016, to unitholders of record on February 15, 2016.
Leave a Reply